CommercialCoverageLow impact
Coverage of Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) for Measles Post-Exposure Prophylaxis in Commercial Members
Independence Blue Cross·Family Medicine, Internal Medicine, Pediatrics +3 more·News & Announcements
Effective date
Jan 16, 2026
We identified it
Jun 19, 2026
Summary
A new policy now provides coverage for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) treatments specifically for measles post-exposure prophylaxis in commercial members. This expands coverage for preventive immunoglobulin therapy following measles exposure.
Action Required
Immediately: Billing team should verify that IVIG and SCIG claims for measles post-exposure prophylaxis are now covered for commercial members. Update billing notes to reflect new coverage policy and ensure proper documentation of measles exposure indication when submitting claims.